We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+11.82%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$328M
AUM Growth
+$81.1M
Cap. Flow
+$76.2M
Cap. Flow %
23.2%
Top 10 Hldgs %
53.81%
Holding
97
New
24
Increased
8
Reduced
15
Closed
50

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.7M
2
ABT icon
Abbott
ABT
+$18.5M
3
TNDM icon
Tandem Diabetes Care
TNDM
+$17.3M
4
CTLT
CATALENT, INC.
CTLT
+$13.9M
5
ARKK icon
ARK Innovation ETF
ARKK
+$13.4M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$12.1M
2
WST icon
West Pharmaceutical
WST
+$8.84M
3
APLS
Apellis Pharmaceuticals
APLS
+$8.36M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.85M
5
STVN icon
Stevanato
STVN
+$6.36M

Sector Composition

Rank Sector Weight
1 Healthcare 95.57%
2 Energy 0.07%
3 Real Estate 0.03%
4 Materials 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PASG icon
76
Passage Bio
PASG
$14.1M
– –
-1,133
Closed -$31K
PCVX icon
77
Vaxcyte
PCVX
$8.76B
– –
-113,477
Closed -$5.44M
PDM
78
Piedmont Realty Trust
PDM
$1.18B
– –
-16,088
Closed -$148K
PTGX icon
79
CALL
Protagonist Therapeutics
PTGX
$9.46B
– –
-199,500
Closed -$2.18M
QNCX icon
80
Quince Therapeutics
QNCX
$28.9M
– –
-111
Closed -$14K
SAFE
81
Safehold
SAFE
$1.13B
– –
-1,858
Closed -$89K
FLNA
82
CALL
Filana Therapeutics
FLNA
$46.3M
– –
-127,200
Closed -$3.76M
SFL icon
83
SFL Corp
SFL
$1.61B
– –
-10,702
Closed -$99K
SYBX
84
DELISTED
Synlogic
SYBX
– –
-1,397
Closed -$16K
TGTX icon
85
TG Therapeutics
TGTX
$7.58B
– –
-288,462
Closed -$3.41M
WU icon
86
Western Union
WU
$2.23B
– –
-11,096
Closed -$153K
XERS icon
87
Xeris Biopharma Holdings
XERS
$1.27B
– –
-36,766
Closed -$49K
RVNC
88
CALL
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-166,300
Closed -$3.07M
TCS
89
DELISTED
THE CONTAINER STORE GROUP, INC.
TCS
– –
-1,002
Closed -$65K
LL
90
DELISTED
LL Flooring Holdings, Inc.
LL
– –
-13,185
Closed -$74K
OMIC
91
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
– –
-541
Closed -$33K
MRTX
92
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-104,598
Closed -$4.74M
LMDX
93
DELISTED
LumiraDx Limited Common Shares
LMDX
– –
-15,621
Closed -$14K
SLGC
94
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
– –
-16,619
Closed -$42K
PRDS
95
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
– –
-19,757
Closed -$33K
RXDX
96
CALL
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-25,700
Closed -$2.83M
PTE
97
DELISTED
PolarityTE, Inc. Common Stock
PTE
– –
-24,743
Closed -$16K
1 2 3
4

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return

Tri Locum Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Tri Locum Partners held 97 positions worth $328M, up 33% from $247M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Tri Locum Partners deployed $76.2M of net new capital in Q1 2023, opening 24 new positions and adding to 8 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 43,389 shares worth $35.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 91% a quarter earlier, followed by Energy and Real Estate.

On the sell side, the largest reduction was West Pharmaceutical, an estimated $8.84M trimmed.

  • Tri Locum Partners's largest Q1 2023 buy was Regeneron Pharmaceuticals: 43,389 shares worth $35.7M.
  • Tri Locum Partners added most to Praxis Precision Medicines in Q1 2023, an estimated $6.93M increase.
  • Tri Locum Partners's biggest Q1 2023 reduction was West Pharmaceutical, cutting an estimated $8.84M.
  • Tri Locum Partners fully exited Ascendis Pharma A/S in Q1 2023, selling an estimated $12.1M.
  • Tri Locum Partners's ten largest holdings make up 54% of its $328M portfolio in Q1 2023.
  • Tri Locum Partners opened 24 new positions and closed 50 in Q1 2023.
  • Tri Locum Partners's portfolio value rose 33% quarter-over-quarter to $328M.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.